Agendia Customer Care is always here to help. For any additional questions or information, please contact one of our friendly representatives:
For US, Canada, Latin America and Oceania, please contact Customer Care toll-free in the US at 888-321-2732, Monday through Friday, 6:00 am to 5:00 pm Pacific Time, or firstname.lastname@example.org
For Europe, Asia or South Africa, please contact Customer Service in The Netherlands at +31 20 462 1500, Monday through Friday, 0830 to 1700, or email@example.com
Your doctor will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.
Only a licensed healthcare professional is qualified to determine if the MammaPrint test is right for you. The test is intended for use in breast cancer patients, with Stage I or Stage II disease, tumor size <5 cm and lymph node negative disease. The test is indicated for use by healthcare providers as a prognostic marker along with other clinicopathological factors. It is not intended to determine the outcome of disease, nor to suggest an individual’s likely response to therapy.
Unlike other similar genomic tests, the Agendia Breast Cancer Suite of tests has no restrictions on other factors such as hormone receptor status (estrogen receptor/progesterone receptor), HER2 status, or hormonal therapy prescription.
A Low Risk result does not guarantee that your cancer will not recur. A High Risk result doesn’t guarantee that your cancer will recur. These results, in addition to all other clinical factors, will help you and your doctor make the most appropriate breast cancer treatment decisions.
As a Low Risk patient, you have an average of 2.2% risk of distant recurrence at 5 years, on hormonal therapy alone (average risk of recurrence for ER-positive / HER2-negative / LN-negative patients).1
High Risk patients can be further divided into subtypes based on the tumor’s genomic profile, which may help to refine your treatment management plan. These subtypes provide additional information about what your tumor may best respond to: hormone therapy, chemotherapy, targeted therapy or a combination.
BluePrint is an 80-gene test that uncovers your tumor’s functional molecular subtype. Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level to see which genes are driving the tumor’s behavior. BluePrint will determine if your breast cancer is Luminal-type (A or B), Basal-type, or HER2-type. These findings are important when deciding which treatment is most appropriate for your specific tumor.
For Canada, Latin America, and Oceania, please contact Customer Care in the US at 888-321-2732 or firstname.lastname@example.org.
For Europe, Asia, or South Africa, please contact Customer Service in The Netherlands at +31 20 462 1500 or email@example.com
In the US, Agendia’s Patient Advocates can be reached at 888-363-7868 or by email at firstname.lastname@example.org.
For Canada, Latin America, and Oceania, please contact Customer Care in the US at (+001) 888-321-2732or email@example.com.
For Europe, Asia, or South Africa, please contact Customer Service in The Netherlands at +31 20 462 1500 or firstname.lastname@example.org.
When an Oncotype DX test comes back with intermediate or Inconclusive results, which occurs between 39% and 67% of the time depending on the study, you may choose to speak with your doctor about the MammaPrint test which will provide either Low Risk or High Risk results. To clarify your specific insurance coverage, please contact an Agendia Patient Advocate representative for more information.
In the US, Agendia’s Patient Advocates can be reached toll-free at 888-363-7868 or by email at email@example.com.
For Canada, Latin America, and Oceania, please contact Customer Care toll-free in the US at (+001) 888-321-2732or firstname.lastname@example.org.
For Europe, Asia, or South Africa, please contact Customer Service in The Netherlands at +31 (0)20 462 1510 or email@example.com.
MINDACT is a population based trial. A risk–benefit assessment and decisions with respect to the use of chemotherapy are highly variable among physicians and patients, and even national and international guidelines differ in their recommendations. Ultimately, the decision to receive or forgo chemotherapy (or any other treatment) lies with each patient who is properly informed about the potential side effects and the potential benefits of such treatment. For the same risk–benefit scenario, different patients may make different decisions.1
MammaPrint is a FDA-cleared in vitro diagnostic test, performed in a single laboratory, using the gene expression profile of breast cancer tissue samples to assess a patients’ risk for distant metastasis. The MammaPrint result is indicated for use by physicians as a prognostic marker only, along with other clinical-pathological factors. MammaPrint is not intended for diagnosis, or to predict or detect response to therapy, or to help select the optimal therapy for patients. Results should be taken in the context of other relevant clinical-pathological factors and standard practice of medicine.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. For more information, visit www.agendia.com.
 Cardoso F, van ’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.
 Glück, S., de Snoo, F., Peeters, J. et al. Breast Cancer Res Treat (2013) 139: 759. doi:10.1007/s10549-013-2572-4
 Carlson JJ, Roth JA. The impact of the Oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014 Jul; 146(1): 233.
 Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373: 2005-14.